Corteva Cuts 2026 Guidance After Brazil Weakness, Shares Fall 8%
Corteva trimmed its full-year 2026 guidance after Brazil weakness and pricing pressure dragged Q3 results, with shares already down 8% and analysts still revising forecasts lower.
Corteva Cuts 2026 Guidance After Brazil Weakness, Shares Fall 8%
NEW YORK, November 12 —
Corteva, Inc. (CTVA) cut full-year 2026 guidance after Brazil market weakness and pricing pressure pulled Q3 results below expectations, sending shares down 8%.
- Shares fell ~8%; FY26 guidance reduced after Brazil weakness and pricing pressure drove a Q3 miss
- Trading at 10.8x forward P/E on $5.0bn TTM revenue declining 1.2% YoY, Simply Wall St still flags CTVA as overvalued after the slide
- Q3 earnings call is the next data point; watch Q3 revenue vs. revised analyst consensus and any Brazil FY27 volume guidance
Brazil Weakness Moved the Full-Year Number, Not Just Q3
Guidance cuts with a geographic explanation are easy to dismiss as one-time noise. This one deserves more scrutiny. Brazil weakness dragged on both Q3 results and the full-year outlook simultaneously, which signals the exposure is large enough to move the annual number even with new-product momentum running in the other direction. For a business with $5.0bn in TTM revenue already down 1.2% YoY, that is a structural overhang, not a weather event.
Analysts Still Revising After the Selloff
The detail the wire rooms will bury: Benzinga's most accurate analysts are updating their models after the stock already dropped that far. Markets move on surprises, and analysts revising estimates downward after a selloff typically means the initial reaction was directionally right but possibly insufficient in scale. If those revised figures still prove too optimistic, the multiple compresses further; there is limited floor at 10.8x on a revenue base that is currently shrinking.
10.8x Forward P/E Assumes the Recovery Arrives on Schedule
At that multiple on $1.62 trailing EPS, the market is pricing in a recovery, not a continuation of the current trend. Simply Wall St's overvaluation flag after the slide is the uncomfortable implication: the discount applied so far may not fully reflect Brazil uncertainty and pricing pressure extending into 2027. The core problem with the valuation is structural: a company that earns only when EM currencies cooperate and input costs ease commands a tighter multiple than one with genuine pricing power.
New Products Provided Real Cover in Q3
The underweighted signal in the Q3 print is that new-product growth and productivity gains actually moved the needle, cushioning the miss rather than just providing talking points for the earnings call. That means the innovation pipeline is functioning. If Brazil stabilizes and pricing pressure eases even modestly in 2027, the same operational leverage that limited the downside could accelerate the recovery. The specific number that would prove the bull case: Brazil volume guidance for FY27 that holds flat or grows. If management offers that on the call, the setup changes.
Generate a full Corteva valuation breakdown at Basis Report's CTVA page, or stress-test the guidance cut against your own assumptions with the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Corteva (CTVA) earnings are imminent with analysts revising forecasts ahead of the call, as new-product growth and productivity gains offset pricing pressure and Brazil weakness.